Hepatitis A Vaccines – Impact of Universal Childhood Vaccination Programmes Vaccine, 1997;15:1157–61.
26. Wallace MR, Brandt CJ, Earhart KC, et al., Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects, Clin Infect Dis, 2004;39:1207–13.
27. Ashur Y, Adler R, Rowe M, et al., Comparison of immunogenicity of two hepatitis A vaccines – VAQTA® and HAVRIX® – in young adults, Vaccine, 1999;17:2290–6.
28. Schmidtke P, Habermehl P, Knuf M, et al., Cell mediated and antibody immune response to inactivated hepatitis A vaccine, Vaccine, 2005;23:5127–32.
29. Garner-Spitzer E, Kundi M, Rendi-Wagner P, et al., Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptors HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees, Vaccine, 2009;27:197–204.
30. Innis BL, Snitbhan R, Kunasol P, et al., Protection against hepatitis A by an inactivated vaccine, JAMA, 1994;271:1328-34.
31. Werzberger A, Mensch B, Kuter B, et al., A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children, N Engl J Med, 1992;327:453–7.
32. Bovier PA, Farinelli T, Loutan L, Interchangeability and tolerability of a virosomal and an aluminium-adsorbed hepatitis A vaccine, Vaccine, 2005;23:2424–9.
33. Bryan JP, Henry CH, Hoffman AG, et al., Randomized, cross- over, controlled comparison of two inactivated hepatitis A vaccines, Vaccine, 2001;19:743–50.
34. Iwarson S, Lindh M, Widerstrom L, Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine, J Travel Med, 2004;11:120–1.
35. Landry P, Tremblay S, Darioli R, et al., Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose, Vaccine, 2000;19:399–402.
36. Iwarson S, Lindh M, Widerstrom L, Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine, Scand J Infect Dis, 2002;34:110–1.
37. Orr N, Klement E, Gillis D, et al., Long-term immunity in young adults after a single dose of inactivated hepatitis A vaccines, Vaccine, 2006;24:4328–32.
38. Vacchino MN, Incidence of Hepatitis A in Argentina after vaccination, J Viral Hepat, 2008;15(Suppl. 2):47–50.
39. Shouval D, Ashur Y, Adler R, et al., Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis, Vaccine, 1993;11(Suppl. 1):S9–14.
40. Van Herck K, Leroux-Roels G, Van Damme P, et al., Ten-year antibody persistence induced by hepatitis A and B vaccine (TwinrixTM) in adults, Travel Med Infect Dis, 2007;5:171–5.
41. Van Herck K, Van Damme P, Lievens M, et al., Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course, J Med Virol, 2004;72:194–6.
42. Werzberger A, Mensch B, Nalin DR, et al., Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years’ follow-up after the Monroe field trial of VAQTA, Vaccine, 2002;20:1699–701.
43. Hammitt LL, Bulkow L, Hennessy TW, et al., Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults, J Infect Dis, 2008;199:1776–82.
44. Van Damme P, Van Herck K, A review of the long-term protection after hepatitis A and B vaccination, Travel Med Infect Dis, 2007;5:79–84.
45. Van Herck K, Van Damme P, Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence, J Med Virol, 2001;63:1–7.
46. Bovier PA, Bock J, Farinelli Ebengo T, et al., Predicted 30-year protection after vaccination with aluminum-free virosomal hepatitis A vaccine, J Med Virol, 2010;82:1629–34.
47. Van Herck K, Beutels P, Van Damme P, et al., Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines, J Med Virol, 2000;60:1–7.
48. WHO, Hepatitis A vaccines, Wkly Epidemiol Rec, 2000;75:38–44. 49. Aarhaug P, Field evaluation of a hepatitis A vaccine in a Norwegian contingent to the United Nations Interim Force in Lebanon, Vaccine, 1992;10(Suppl. 1):S156–8.
50. DeFraites RF, Feighner BH, Binn LN, et al., Immunisation of
US soldiers with a two-dose primary series of inactivated hepatitis A vaccine: early immune response, persistence of antibody, and response to a third dose at 1 year, J Infect Dis, 1995;171(Suppl. 1):S61–9.
51. Gillis D, Grotto I, Mimouni D, et al., Adult infection with hepatitis A despite declining endemicity; in favor of adult vaccination, Vaccine, 2002;20:2243–8.
52. Gillis D, Yetiv N, Gdalevich M, et al., Active versus passive immunisation against hepatitis A in the Israel defence forces: a cost-benefit analysis, Vaccine, 2000;18:3005–10.
53. Hoke Jr CH, Binn LN, Egan JE, et al., Hepatitis A in the US Army: epidemiology and vaccine development, Vaccine, 1992;10(Suppl. 1):S75–9.
54. Staes CJ, L. ST, Risk I, et al., Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak, Pediatrics, 2000;106:e54.
55. Prikazsky V, Olear V, Cernoch A, et al., Interruption of an outbreak of hepatitis A in two villages by vaccination, J Med Virol, 1994;44:457–9.
56. Zamir C, Rishpon S, Zamir D, et al., Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine, Eur J Clin Microbiol Infect Dis, 2001;20:185–7.
57. Castkova J, Benes C, Increase in hepatitis A cases in the Czech Republic in 2008 – an update, Euro Surveill, 2009;14:19091.
58. Perevoscikovs J, Lucenko I, Magone S, et al., Community- wide outbreak of hepatitis A in Latvia in 2008 – an update, Euro Surveill, 2009;14:19092.
59. Selnikova O, Moisseeva A, Zadorozhnaja V, et al., Hepatitis A vaccination effectiveness during an outbreak in the Ukraine, Vaccine, 2008;26:3135–7.
60. Victor JC, Monto AS, Surdina TY, et al., Hepatitis A vaccine versus immune globulin for postexposure prophylaxis, N Engl J Med, 2007;357:1685–94.
61. Craig AS, Sockwell DC, Schaffner W, et al., Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A, Clin Infect Dis, 1998;27:531–5.
62. Dagan R, Leventhal A, Anis E, et al., Incidence of hepatitis A in Israel following universal immunisation of toddlers, JAMA, 2005;294:202–10.
63. Chodick G, Heymann AD, Ashkenazi S, et al., Long-term trends in hepatitis A incidence following the inclusion of hepatitis A vaccine in the routine nationwide immunisation program, J Viral Hepat, 2008;15:62–5.
64. Bialek SR, Thoroughman DA, Hu D, et al., Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska natives, 1990-2001, Am J Public Health, 2004;94:996–1001.
65. Averhoff F, Shapiro CN, Bell BP, et al., Control of hepatitis A through routine vaccination of children, JAMA, 2001;286:2968–73.
66. Wasley A, Samandari T, Bell BP, Incidence of hepatitis A in the United States in the era of vaccination, JAMA, 2005;294:194-201.
67. CDC, Prevention of hepatitis A through active or passive immunisation: recommendations of the Advisory Committee on Immunisation Practices (ACIP), MMWR Recomm Rep, 1999;48:1–37.
68. Samandari T, Bell BP, Armstrong GL, Quantifying the impact of hepatitis A immunisation in the United States, 1995–2001, Vaccine, 2004;22:4342–50.
69. Lopalco PL, Prato R, Chironna M, et al., Control of hepatitis A by universal vaccination of adolescents, Puglia, Italy, Emerg Infect Dis, 2008;14:526–8.
70. Lopalco PL, Salleras L, Barbuti S, et al., Hepatitis A and B in children and adolescents – what can we learn from Puglia (Italy) and Catalonia (Spain)?, Vaccine, 2001;19:470–4.
71. Dominguez A, Salleras L, Carmona G, et al., Effectiveness of a mass hepatitis A vaccination program in preadolescents, Vaccine, 2003;21:698–701.
72. Hanna JN, Hills SL, Humphreys JL, Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland, Med J Aust, 2004;181:482–5. 73. Baranov AA, Enteric infections control by immunisation in
Belarus, Ukraine, Kazakhstan and Russia. The consensus statement of experts of EEVag group, Epidemiology Vacc, 2008;6:3–17.
74. Mukomolov SL, Stalevskaya AV, Zheleznova NV, et al., Seroepidemiology of hepatitis A in St. Petersburg in 2009, J Microbiol Epidemiol Immunobiol, 2010;5:15–20.
75. Kharit SM, Vaccination: problems and perspectives, Infect J, 2009;1:61–5.
76. Shakhguildyan IV, Michailov MI, Ershova ON, et al., Hepatitis A vaccination efficacy to prevent and terminate outbreaks in Russian Federation, Epidemiol Infect Dis, 2009;2:63–4.
77. Shakhguildyan IV, Michailov MI, Ershova ON, et al., Modern epidemiological features of hepatitis A and efficacy of universal mass vaccination in children, Mod Pediatrics, 2010;9:56–60.
78. Fisenka EG, Germanovich FA, Glinskaya IN, et al., Effectiveness of universal hepatitis A immunisation of children in Minsk City, Belarus: four-year follow-up, J Viral Hepat, 2008;15:57–61.
79. Rosenthal P, Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults, Hepatology, 2003;37:44–51.
80. Rein DB, Hicks KA, Wirth KE, et al., Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States, Pediatrics, 2007;119:e12–21.
81. Anonychuk AM, Tricco AC, Bauch CT, et al., Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies, Pharmacoeconomics, 2008;26:17–32.
82. Szucs T, Cost-effectiveness of hepatitis A and B vaccination programme in Germany, Vaccine, 2000;18:S86–9.
83. Ginsberg GM, Slater PE, Shouval D, Cost-benefit analysis of a nationwide infant immunisation programme against hepatitis A in an area of intermediate endemicity, J Hepatol, 2001;34:92–9.
84. Armstrong GL, Billah K, Rein DB, et al., The economics of routine childhood hepatitis A immunisation in the United States: the impact of herd immunity, Pediatrics, 2007;119:e22–9.
85. Ellis A, Ruttimann RW, Jacobs RJ, et al., Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted, Rev Panam Salud Publica, 2007;21:345–56.
86. Lopez E, Debbag R, Coudeville L, et al., The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis, J Gastroenterol, 2007;42:152–60.
87. Zhuang G-H, Pan X-J, Wang X-L, A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China, Vaccine, 2008;26:4608–16.
88. Zahdi MR, Maluf IJ, Maluf EMCP, Hepatitis A: the costs and benefits of the disease prevention by vaccine, Paraná, Brazil, Braz J Infect Dis, 2009;13:257–61.
89. Quezada A, Baron-Papillon F, Coudeville L, et al., Universal vaccination of children against hepatitis A in Chile: a cost-effectiveness study, Rev Panam Salud Publica, 2008;23:303–12.
90. Valenzuela MT, Jacobs RJ, Arteaga O, et al., Cost- effectiveness of universal childhood hepatitis A vaccination in Chile, Vaccine, 2005;23:4110–9.
91. Mathur P, Arora NK, Considerations of HAV vaccine in India, Indian J Pediatr, 1999;66:111–20.
92. Soogarun S, Wiwanitkit V, Vaccinating Thai adolescents against hepatitis A: is it cost-effective?, Southeast Asian J Trop Med Public Health, 2002;33:145–8.
93. Poland GA, Evaluating existing recommendations for hepatitis A and B vaccination, Am J Med, 2005;118(Suppl. 10A):16S–20S.
94. Scheifele DW, Hepatitis A vaccines: the growing case for universal immunisation of children, Expert Opin Pharmacother, 2005;6:157–64.
95. Torner N, Broner S, Martinez A, et al., Hepatitis A outbreaks: the effect of a mass vaccination programme, J Viral Hepat, 2011;18(4):e1–4.
96. Klevens RM, Miller JT, Iqbal K, et al., The evolving epidemiology of hepatitis A in the United States, Arch Intern Med, 2010;170:1811–8.
EUROPEAN GASTROENTEROLOGY & HEPATOLOGY REVIEW
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84